  Multifunctional nanomaterials combining diagnosis and therapeutic properties
have attracted a considerable attention in cancer research. Yet some important
challenges are still to be faced, including an optimal coupling between these
two types of properties that would be effective within complex biological
tissues. To address these points, we have prepared novel nanoplatforms
associating controlled drug delivery of doxorubicin and Magnetic Resonance
Imaging (MRI) contrast-enhancement that exhibit high specificity towards cancer
cells compared to normal cells and evaluated them both in 2D cultures and
within 3D tissue-like biomimetic matrices. Methods: Nanoplatforms were prepared
from hollow silica nanoparticles coated with MnO2 nanosheets and conjugated
with the AS1411 aptamer as a targeting agent. They were fully characterized
from a chemical and structural point of view as well as for drug release and
MRI signal enhancement. Standard two-dimensional monolayer cultures were
performed using HeLa and Normal Human Dermal Fibroblasts (NHDF) cells to
testify targeting and cytotoxicity. Cellularized type I collagen-based
hydrogels were also used to study nanoparticles behavior in 3D biomimetic
environments. Results: The as-established nanoplatforms can enter HeLa cells,
leading to the dissociation of the MnO2 nanosheets into Mn 2+ that enhanced T1
magnetic resonance signals and concomitantly release doxorubicin, both effects
being markedly more significant than in the presence of NHDFs. Moreover,
particles functionality and specificity were preserved when the cells were
immobilized within type I collagen-based fibrillar hydrogels. Conclusion: The
use of MnO2 nanosheets as glutathione-sensitive coatings of drug loaded
nanoparticles together with surface conjugation with a targeting aptamer offers
an effective strategy to obtain efficient and specific nanotheranostic systems
for cancer research, both in 2D and 3D. The here-described tissue-like models
should be easy to implement and could constitute an interesting intermediate
validation step for newly-developed theranostic nanoparticles before in vivo
evaluation.
